Status:
RECRUITING
Combined Exercise and Nutritional Intervention in GI Cancer Patients
Lead Sponsor:
Hospital Beatriz Ângelo
Conditions:
Pancreatic Cancer
Gastric Cancer
Eligibility:
All Genders
40-80 years
Phase:
NA
Brief Summary
Although some studies have focused on the role of exercise on inflammation and cytokine expression in cancer patients undergoing treatment and survivors, to our knowledge none have investigated the ef...
Eligibility Criteria
Inclusion
- gastric or pancreatic cancer stage II/III, eligible for neoadjuvant chemotherapy,
- age higher than 40 years and lower than 80 years,
- ECOG (Eastern Cooperative Oncology Group) functional status: 0-2,
- sedentary/low physical activity level.
Exclusion
- life expectancy less than 12 months at inclusion,
- chemotherapy regimen other than 5-Fluorouracil, Folinic acid, Oxaliplatin, Docetaxel (FLOT) for gastric and 5-Fluorouracil, Irinotecan and Oxaliplatin (FOLFIRINOX) or gemcitabine for pancreatic cancer,
- metastatic disease,
- chronic anti-inflammatory medication use,
- known inflammatory condition (rheumatoid arthritis, ankylosing spondylitis or chronic active hepatitis)
- cardiovascular, respiratory or musculoskeletal or joint problems that preclude moderate physical activity.
Key Trial Info
Start Date :
March 21 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 28 2024
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT05420259
Start Date
March 21 2022
End Date
June 28 2024
Last Update
March 19 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Beatriz Ângelo
Loures, Lisbon District, Portugal, 2674-514
2
Hospital da Luz
Lisbon, Portugal